See more : FGV Holdings Berhad (5222.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Techne Corporation (TECH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Techne Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jilin Chemical Fibre Stock Co.,Ltd (000420.SZ) Income Statement Analysis – Financial Results
- Fortis Inc. (FTS) Income Statement Analysis – Financial Results
- Shenzhen International Holdings Limited (0152.HK) Income Statement Analysis – Financial Results
- Gadsden Properties, Inc. (GADS) Income Statement Analysis – Financial Results
- FluoGuide A/S (FLUO.ST) Income Statement Analysis – Financial Results
Bio-Techne Corporation (TECH)
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.16B | 1.14B | 1.11B | 931.03M | 738.69M | 714.01M | 642.99M | 563.00M | 499.02M | 452.25M | 357.76M | 310.58M | 314.56M | 289.96M | 269.05M | 263.96M | 257.42M | 223.48M | 202.62M | 178.65M | 161.26M | 145.01M | 130.90M | 115.36M | 103.84M | 90.90M | 67.30M | 60.90M | 54.60M | 47.70M | 40.30M | 28.70M | 22.30M | 19.30M | 15.70M | 12.50M |
| Cost of Revenue | 389.34M | 366.89M | 349.10M | 298.18M | 255.50M | 240.52M | 210.85M | 188.46M | 162.36M | 144.97M | 106.35M | 79.47M | 78.76M | 65.03M | 54.46M | 55.49M | 52.89M | 46.67M | 45.72M | 36.81M | 34.89M | 35.40M | 32.51M | 28.42M | 23.33M | 25.00M | 17.80M | 17.00M | 17.10M | 16.80M | 15.20M | 11.80M | 9.60M | 8.90M | 7.30M | 6.10M |
| Gross Profit | 769.73M | 769.82M | 756.50M | 632.85M | 483.19M | 473.49M | 432.14M | 374.54M | 336.66M | 307.28M | 251.41M | 231.11M | 235.80M | 224.94M | 214.58M | 208.47M | 204.53M | 176.82M | 156.90M | 141.84M | 126.37M | 109.61M | 98.39M | 86.93M | 80.51M | 65.90M | 49.50M | 43.90M | 37.50M | 30.90M | 25.10M | 16.90M | 12.70M | 10.40M | 8.40M | 6.40M |
| Gross Profit Ratio | 66.41% | 67.72% | 68.42% | 67.97% | 65.41% | 66.31% | 67.21% | 66.53% | 67.46% | 67.94% | 70.27% | 74.41% | 74.96% | 77.57% | 79.76% | 78.98% | 79.45% | 79.12% | 77.44% | 79.39% | 78.37% | 75.59% | 75.17% | 75.36% | 77.53% | 72.50% | 73.55% | 72.09% | 68.68% | 64.78% | 62.28% | 58.89% | 56.95% | 53.89% | 53.50% | 51.20% |
| Research & Development | 96.66M | 92.49M | 87.14M | 70.60M | 65.19M | 62.41M | 55.33M | 53.51M | 45.19M | 40.85M | 30.95M | 29.26M | 27.91M | 25.99M | 25.12M | 23.56M | 22.39M | 20.08M | 18.83M | 18.38M | 20.77M | 20.58M | 17.47M | 14.52M | 11.20M | 12.00M | 10.60M | 11.70M | 10.40M | 8.60M | 6.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 396.83M | 352.44M | 339.00M | 289.92M | 240.88M | 236.87M | 240.64M | 153.33M | 140.88M | 119.40M | 60.72M | 43.38M | 41.68M | 35.90M | 32.18M | 33.16M | 36.72M | 30.97M | 27.60M | 24.48M | 21.73M | 19.38M | 19.55M | 17.71M | 17.32M | 16.90M | 15.40M | 14.60M | 13.00M | 11.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 25.94M | 33.77M | 35.03M | 19.70M | 27.49M | 0.00 | 45.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 396.83M | 378.38M | 372.77M | 324.95M | 260.58M | 264.36M | 240.64M | 199.24M | 140.88M | 119.40M | 60.72M | 43.38M | 41.68M | 35.90M | 32.18M | 33.16M | 36.72M | 30.97M | 27.60M | 24.48M | 21.73M | 19.38M | 19.55M | 17.71M | 17.32M | 16.90M | 15.40M | 14.60M | 13.00M | 11.20M | 9.20M | 8.70M | 7.60M | 7.70M | 6.60M | 5.60M |
| Other Expenses | 0.00 | 39.72M | 4.80M | -89.12M | 119.06M | -34.70M | -10.23M | -8.56M | -3.11M | 7.14M | -1.04M | 830.00K | 693.00K | 0.00 | 960.00K | 960.00K | 1.14M | 1.61M | 1.97M | 1.22M | 1.60M | 1.94M | 8.55M | 8.89M | 12.65M | 11.90M | 2.30M | 2.30M | 1.90M | 1.70M | 11.00M | 10.00M | 8.60M | 8.20M | 6.90M | 5.80M |
| Operating Expenses | 563.04M | 470.87M | 459.91M | 395.55M | 325.78M | 326.77M | 295.97M | 252.76M | 186.07M | 160.25M | 91.66M | 74.83M | 71.72M | 61.88M | 58.26M | 57.69M | 60.24M | 52.66M | 48.40M | 44.08M | 44.10M | 41.90M | 45.57M | 41.13M | 41.16M | 40.80M | 28.30M | 28.60M | 25.30M | 21.50M | 17.50M | 10.00M | 8.60M | 8.20M | 6.90M | 5.80M |
| Cost & Expenses | 952.37M | 837.76M | 809.01M | 693.74M | 581.27M | 567.29M | 506.82M | 441.22M | 348.43M | 305.22M | 198.01M | 154.30M | 150.48M | 126.91M | 112.72M | 113.18M | 113.13M | 99.33M | 94.11M | 80.89M | 78.98M | 77.29M | 78.08M | 69.55M | 64.49M | 65.80M | 46.10M | 45.60M | 42.40M | 38.30M | 32.70M | 21.80M | 18.20M | 17.10M | 14.20M | 11.90M |
| Interest Income | 3.32M | 3.41M | 794.00K | 473.00K | 605.00K | 569.00K | 409.00K | 304.00K | 249.00K | 634.00K | 2.68M | 2.65M | 2.64M | 3.75M | 4.38M | 7.63M | 12.19M | 8.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.74M | 11.22M | 11.31M | 13.95M | 19.20M | 21.71M | 10.19M | 7.36M | 1.75M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.71M | 107.24M | 101.07M | 87.75M | 82.74M | 78.17M | 64.46M | 60.04M | 42.76M | 37.23M | 19.18M | 12.32M | 12.47M | 8.70M | 960.00K | 7.77M | 7.26M | 6.99M | 6.96M | 6.11M | 6.04M | 6.35M | 12.69M | 12.74M | 12.65M | 11.90M | 2.30M | 2.30M | 1.90M | 1.70M | 1.80M | 1.30M | 1.00M | 500.00K | 300.00K | 200.00K |
| EBITDA | 310.37M | 460.57M | 420.12M | 258.47M | 373.91M | 211.89M | 200.60M | 179.36M | 191.99M | 192.93M | 180.57M | 172.98M | 174.66M | 173.68M | 164.58M | 158.55M | 151.55M | 137.01M | 115.46M | 103.87M | 88.31M | 74.07M | 65.51M | 58.54M | 52.00M | 37.00M | 23.50M | 17.60M | 14.10M | 11.10M | 9.40M | 8.20M | 5.10M | 2.70M | 1.80M | 800.00K |
| EBITDA Ratio | 26.78% | 35.73% | 35.97% | 25.49% | 21.31% | 20.55% | 21.18% | 21.63% | 30.18% | 32.51% | 44.65% | 54.18% | 57.59% | 59.86% | 60.04% | 62.96% | 59.90% | 59.84% | 57.52% | 58.79% | 56.19% | 51.16% | 63.41% | 50.75% | 50.07% | 39.71% | 33.14% | 27.75% | 25.09% | 22.85% | 24.32% | 29.97% | 26.01% | 13.47% | 10.83% | 5.60% |
| Operating Income | 206.69M | 298.94M | 296.59M | 149.55M | 74.68M | 125.58M | 136.18M | 121.78M | 150.59M | 147.02M | 159.75M | 158.47M | 166.21M | 163.06M | 156.33M | 150.78M | 144.29M | 124.15M | 108.50M | 97.76M | 82.27M | 67.72M | 52.82M | 45.81M | 39.34M | 25.10M | 21.20M | 15.30M | 12.20M | 9.40M | 7.60M | 6.90M | 4.10M | 2.20M | 1.50M | 600.00K |
| Operating Income Ratio | 17.83% | 26.30% | 26.83% | 16.06% | 10.11% | 17.59% | 21.18% | 21.63% | 30.18% | 32.51% | 44.65% | 51.02% | 52.84% | 56.23% | 58.10% | 57.12% | 56.05% | 55.55% | 53.55% | 54.72% | 51.02% | 46.70% | 40.35% | 39.71% | 37.89% | 27.61% | 31.50% | 25.12% | 22.34% | 19.71% | 18.86% | 24.04% | 18.39% | 11.40% | 9.55% | 4.80% |
| Total Other Income/Expenses | -21.00M | 39.72M | 4.80M | -89.12M | 119.06M | -34.70M | -10.23M | -8.62M | -3.11M | 7.14M | 1.64M | 2.19M | -4.01M | 1.93M | 118.00K | 4.58M | 9.54M | 4.78M | 2.66M | 2.12M | 268.00K | 1.84M | -15.08M | 2.00M | 66.98K | 1.00M | 1.20M | 700.00K | 400.00K | 200.00K | -400.00K | -400.00K | -800.00K | 0.00 | -100.00K | 0.00 |
| Income Before Tax | 185.69M | 338.66M | 301.39M | 148.18M | 276.48M | 112.02M | 125.95M | 113.16M | 147.48M | 154.16M | 161.39M | 160.66M | 162.20M | 164.98M | 156.45M | 155.36M | 153.83M | 128.93M | 111.16M | 99.89M | 82.54M | 69.56M | 37.74M | 47.81M | 39.41M | 26.10M | 22.40M | 16.00M | 12.60M | 9.60M | 7.20M | 6.50M | 3.30M | 2.20M | 1.40M | 600.00K |
| Income Before Tax Ratio | 16.02% | 29.79% | 27.26% | 15.92% | 37.43% | 15.69% | 19.59% | 20.10% | 29.55% | 34.09% | 45.11% | 51.73% | 51.56% | 56.90% | 58.15% | 58.86% | 59.76% | 57.69% | 54.86% | 55.91% | 51.19% | 47.97% | 28.83% | 41.44% | 37.96% | 28.71% | 33.28% | 26.27% | 23.08% | 20.13% | 17.87% | 22.65% | 14.80% | 11.40% | 8.92% | 4.80% |
| Income Tax Expense | 17.58M | 53.22M | 38.29M | 8.59M | 47.18M | 15.94M | 602.00K | 35.88M | 43.01M | 46.43M | 50.44M | 48.10M | 49.86M | 52.68M | 46.67M | 50.12M | 50.27M | 43.82M | 37.81M | 33.76M | 29.61M | 24.16M | 10.61M | 13.76M | 12.83M | 9.40M | 7.20M | 5.10M | 4.00M | 2.90M | 2.10M | 2.10M | 1.30M | 600.00K | 400.00K | 200.00K |
| Net Income | 168.11M | 285.26M | 272.05M | 140.41M | 229.30M | 96.07M | 125.35M | 77.29M | 104.48M | 107.74M | 110.95M | 112.56M | 112.33M | 112.30M | 109.78M | 105.24M | 103.56M | 85.11M | 73.35M | 66.13M | 52.93M | 45.40M | 27.13M | 34.05M | 26.58M | 16.70M | 15.20M | 10.90M | 8.60M | 6.70M | 5.10M | 4.40M | 2.00M | 1.60M | 1.00M | 400.00K |
| Net Income Ratio | 14.50% | 25.10% | 24.61% | 15.08% | 31.04% | 13.46% | 19.49% | 13.73% | 20.94% | 23.82% | 31.01% | 36.24% | 35.71% | 38.73% | 40.80% | 39.87% | 40.23% | 38.08% | 36.20% | 37.02% | 32.82% | 31.31% | 20.73% | 29.51% | 25.60% | 18.37% | 22.59% | 17.90% | 15.75% | 14.05% | 12.66% | 15.33% | 8.97% | 8.29% | 6.37% | 3.20% |
| EPS | 1.07 | 1.81 | 1.73 | 0.91 | 1.50 | 0.64 | 0.84 | 0.52 | 0.70 | 0.73 | 0.75 | 0.76 | 0.76 | 0.76 | 0.74 | 0.70 | 0.66 | 0.54 | 0.47 | 0.41 | 0.32 | 0.27 | 0.16 | 0.21 | 0.16 | 0.10 | 0.10 | 0.07 | 0.06 | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 |
| EPS Diluted | 1.05 | 1.76 | 1.66 | 0.87 | 1.45 | 0.62 | 0.82 | 0.52 | 0.70 | 0.72 | 0.75 | 0.76 | 0.76 | 0.76 | 0.73 | 0.69 | 0.66 | 0.54 | 0.46 | 0.40 | 0.32 | 0.27 | 0.16 | 0.20 | 0.16 | 0.10 | 0.10 | 0.07 | 0.06 | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 157.71M | 157.18M | 156.88M | 154.99M | 152.80M | 151.12M | 149.90M | 149.25M | 148.78M | 148.38M | 147.56M | 147.34M | 147.76M | 148.39M | 149.02M | 151.21M | 156.56M | 157.62M | 156.20M | 161.44M | 164.18M | 165.48M | 166.03M | 165.75M | 162.50M | 160.94M | 151.62M | 150.34M | 155.54M | 152.35M | 145.71M | 146.67M | 133.33M | 128.00M | 133.33M | 126.14M |
| Weighted Avg Shares Out (Dil) | 160.77M | 161.86M | 164.12M | 161.93M | 157.60M | 155.57M | 152.22M | 150.00M | 149.30M | 148.92M | 148.02M | 147.60M | 148.02M | 148.69M | 149.39M | 151.60M | 156.99M | 158.05M | 158.38M | 163.68M | 166.79M | 168.12M | 170.09M | 170.67M | 168.82M | 165.49M | 156.86M | 155.71M | 155.54M | 153.33M | 145.71M | 146.67M | 133.33M | 128.00M | 133.33M | 126.14M |
Should You Continue to Retain Bio-Techne Stock in Your Portfolio?
Bio-Techne's success with four growth verticals and expansion through acquisitions bode well.
Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE
MINNEAPOLIS , Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A...
Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne
WEST SACRAMENTO, Calif. , Nov. 25, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today...
OverT Bio Receives $120K G-Rex® Grant to Propel Solid Tumor Cell Therapy Advancements
NEW YORK--(BUSINESS WIRE)--OverT Bio, an NYC-based cell therapy company, today announced that it has been awarded a $120,000 G-Rex Grant from ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM. This grant will support OverT Bio's...
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES
MINNEAPOLIS , Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement,...
BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH
MINNEAPOLIS , Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform...
BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO
Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees MINNEAPOLIS , Nov. 14, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its lineup of presentations and activities...
UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS
R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation This press release updates the IVDR Classification to Class B from the prior Class C. MINNEAPOLIS , Nov. 11, 2024...
BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS
R&D Systems Hematology Controls and Calibrators has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation MINNEAPOLIS , Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for...
Source: https://incomestatements.info
Category: Stock Reports